FDA OKs Takeda, Protagonist drug for rare blood cancer
RegulatoryapprovedMimryloPositive
AI Analysis
Summary
The FDA approved Mimrylo, a Takeda and Protagonist collaboration, for rare blood cancer with a broader-than-expected label. Analysts project annual revenue potential of $2 billion or more.
Financial Highlights
Revenue
$2 billion or more annually
Outcome Details
FDA approval with broader-than-expected label
Importance:8/10
Sentiment:
0.90
FDA approvalrare diseasehematologylabel expansion
Read the original article
Published by BioPharma Dive on August 31, 2026 4:13 PM